ClinicalTrials.gg
CompletedNCT05999513ARC-28Updated Oct 17, 2024

A Relative Bioavailability Study and Food Effect Study of AB521 in Healthy Adult Volunteers

A Phase 1 interventional study of casdatifan in Healthy Participants, sponsored by Arcus Biosciences, Inc.. Completed at 1 site in United States. Open to participants aged 19 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-10-17.

Sponsored by Arcus Biosciences, Inc. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Oct 2023, 3 years ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
19 Years to 55 Years
Sex
All
01

Study summary

The primary purpose of this study is to compare the single-dose pharmacokinetics (PK) of casdatifan tablet versus the casdatifan capsule, and to evaluate the effect of food on the single-dose PK of casdatifan tablet in healthy adult volunteers.

02

Conditions studied

  • Healthy Participants

Keywords

  • AB521
  • casdatifan
03

In context

Lead sponsor

Arcus Biosciences, Inc. is the lead sponsor of 32 studies on the registry; 4 are open to participants now.

Of its 23 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
19 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Key Inclusion Criteria:

  • Continuous non-smoker who has not used nicotine- and tobacco-containing products for at least 3 months prior to the first dosing based on volunteer self-reporting
  • (BMI) ≥ 18.0 and ≤ 32.0 kilogram (kg)/square meter (m\^2) at the screening visit, with body weight ≥ 45 kg
  • Medically healthy with no medical history, physical examination, laboratory profiles, vital signs, and ECGs, as deemed by the study physician
  • Able to swallow multiple capsules and tablets
  • Has adequate peripheral venous access

Key Exclusion Criteria:

  • Has active neoplastic disease or history of neoplastic disease within 5 years of the screening visit (except for basal or squamous cell carcinoma of the skin or carcinoma in situ that has been definitively treated with standard of care)
  • Has abnormal liver enzyme test results or hematology values at the time of enrollment
  • Has a history of additional risk factors for Torsades de pointes (example: heart failure, hypokalemia, family history of Long Syndrome)
  • Malabsorption condition that would alter the absorption of orally administered medications at the discretion of the study physician
  • Participation in another clinical study within 90 days or within 5 half-lives (if known), prior to the first dosing, whichever is longer. The 90-day window will be derived from the date of the last blood collection or dosing, whichever is later, in the previous study to Day 1 of the current study

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    Casdatifan - Sequence ABC

    Participants will sequentially receive casdatifan capsules fasted (Treatment A), followed by casdatifan tablets fasted (Treatment B), followed by casdatifan tablets fed (Treatment C)

    Drug: casdatifan

  • Experimental
    Casdatifan - Sequence BCA

    Participants will sequentially receive Treatment B, followed by Treatment C, then Treatment A

    Drug: casdatifan

  • Experimental
    Casdatifan - Sequence CAB

    Participants will sequentially receive Treatment C, followed by Treatment A, then Treatment B

    Drug: casdatifan

Interventions

  • Administered as specified in the treatment arm

    Also known as: AB521

06

What researchers measure

Primary outcomes

  1. Area Under the Plasma Drug Concentration-Time Curve (AUC)

    Time frame: Predose, Up to 168 hours postdose

  2. Maximum Concentration (Cmax)

    Time frame: Predose, Up to 168 hours postdose

  3. Time to Maximum Concentration (Tmax)

    Time frame: Predose, Up to 168 hours postdose

  4. Terminal Half-Life Time (t1/2)

    Time frame: Predose, Up to 168 hours postdose

  5. Apparent Total Plasma Clearance (CL/F)

    Time frame: Predose, Up to 168 hours postdose

  6. Apparent Volume of Distribution During the Terminal Elimination Phase (Vz/F)

    Time frame: Predose, Up to 168 hours postdose

Secondary outcomes

  1. Number of Participants With Adverse Events

    Time frame: Up to 10 weeks

07

Study locations

1 site
  • Celerion, Inc.
    Lincoln, Nebraska 68502, United States
08

References and documents

Individual participant data

Plan to share: Yes — Arcus will provide access to individual de-identified participant data and related study documents (e.g., protocol, Statistical Analysis Plan [SAP], Clinical Study Report [CSR]) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. For more information, please visit our website.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Data sharing details ↗ · trials.arcusbio.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2023 to primary completion in Oct 2023, 2 months.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 14, 2023
First posted
Aug 21, 2023
StartActual
Aug 21, 2023
Primary completionActual
Oct 31, 2023
CompletionActual
Oct 31, 2023
Last update
Oct 17, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 17, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05999513
Responsible party
Sponsor
First posted
Aug 21, 2023
Start date
Aug 21, 2023
Primary completion
Oct 31, 2023
Completion
Oct 31, 2023
Last update
Oct 17, 2024

Study contacts

Medical Director
study director · Arcus Biosciences

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Casdatifan

Start the discussion